Literature DB >> 25003763

Eosinophils in vasculitis: characteristics and roles in pathogenesis.

Paneez Khoury1, Peter C Grayson2, Amy D Klion1.   

Abstract

Eosinophils are multifunctional granular leukocytes that are implicated in the pathogenesis of a wide variety of disorders, including asthma, helminth infection, and rare hypereosinophilic syndromes. Although peripheral and tissue eosinophilia can be a feature of many types of small-vessel and medium-vessel vasculitis, the role of eosinophils has been best studied in eosinophilic granulomatosis with polyangiitis (EGPA), where eosinophils are a characteristic finding in all three clinical stages of the disorder. Whereas numerous studies have demonstrated an association between the presence of eosinophils and markers of eosinophil activation in the blood and tissues of patients with EGPA, the precise role of eosinophils in disease pathogenesis has been difficult to ascertain owing to the complexity of the disease process. In this regard, results of clinical trials using novel agents that specifically target eosinophils are providing the first direct evidence of a central role of eosinophils in EGPA. This Review focuses on the aspects of eosinophil biology most relevant to the pathogenesis of vasculitis and provides an update of current knowledge regarding the role of eosinophils in EGPA and other vasculitides.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25003763      PMCID: PMC4849122          DOI: 10.1038/nrrheum.2014.98

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  119 in total

1.  Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production.

Authors:  R J Pepper; M A Fabre; C Pavesio; G Gaskin; R B Jones; D Jayne; C D Pusey; A D Salama
Journal:  Rheumatology (Oxford)       Date:  2008-05-20       Impact factor: 7.580

2.  [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children].

Authors:  T Kawasaki
Journal:  Arerugi       Date:  1967-03

3.  Activation of neutrophils, eosinophils, and lymphocytes in the lower respiratory tract in Wegener's granulomatosis.

Authors:  A Schnabel; E Csernok; J Braun; W L Gross
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

Review 4.  Inhibition of interleukin-5 for the treatment of eosinophilic diseases.

Authors:  Jonathan Corren
Journal:  Discov Med       Date:  2012-04       Impact factor: 2.970

5.  CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome.

Authors:  Tomáš Dallos; Gisela Ruiz Heiland; Johanna Strehl; Thomas Karonitsch; Wolfgang L Gross; Frank Moosig; Constanze Holl-Ulrich; Jörg H W Distler; Bernhard Manger; Georg Schett; Jochen Zwerina
Journal:  Arthritis Rheum       Date:  2010-11

Review 6.  Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome.

Authors:  J G Lanham; K B Elkon; C D Pusey; G R Hughes
Journal:  Medicine (Baltimore)       Date:  1984-03       Impact factor: 1.889

7.  Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease.

Authors:  A Slungaard; G M Vercellotti; T Tran; G J Gleich; N S Key
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

8.  Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially.

Authors:  Lisa A Spencer; Craig T Szela; Sandra A C Perez; Casey L Kirchhoffer; Josiane S Neves; Amy L Radke; Peter F Weller
Journal:  J Leukoc Biol       Date:  2008-10-07       Impact factor: 4.962

9.  Neuropathy in the hypereosinophilic syndrome.

Authors:  L J Dorfman; B R Ransom; L S Forno; A Kelts
Journal:  Muscle Nerve       Date:  1983-05       Impact factor: 3.217

10.  Type 2 innate lymphoid cells control eosinophil homeostasis.

Authors:  Jesse C Nussbaum; Steven J Van Dyken; Jakob von Moltke; Laurence E Cheng; Alexander Mohapatra; Ari B Molofsky; Emily E Thornton; Matthew F Krummel; Ajay Chawla; Hong-Erh Liang; Richard M Locksley
Journal:  Nature       Date:  2013-09-15       Impact factor: 49.962

View more
  40 in total

1.  Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.

Authors:  Jonathan Steinfeld; Eric S Bradford; Judith Brown; Stephen Mallett; Steven W Yancey; Praveen Akuthota; Maria C Cid; Gerald J Gleich; David Jayne; Paneez Khoury; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Peter F Weller; Michael E Wechsler
Journal:  J Allergy Clin Immunol       Date:  2018-12-19       Impact factor: 10.793

2.  Aggressive eosinophilic granulomatosis with polyangiitis and transverse sinus thrombosis.

Authors:  Snegha Ananth; Rajeswari Sankaralingam; Manesh Manoj
Journal:  BMJ Case Rep       Date:  2016-01-12

Review 3.  Eosinophilic Vasculitis.

Authors:  Karen L Vega Villanueva; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2020-01-11       Impact factor: 4.592

4.  Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis.

Authors:  Peter C Grayson; Paul A Monach; Christian Pagnoux; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Kathleen Maksimowicz-McKinnon; Philip Seo; Ulrich Specks; Steven R Ytterberg; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2014-11-17       Impact factor: 7.580

5.  Vasculitis: Mepolizumab for eosinophilic granulomatosis with polyangiitis.

Authors:  Loïc Guillevin
Journal:  Nat Rev Rheumatol       Date:  2017-08-03       Impact factor: 20.543

6.  Could hypereosinophilia at diagnosis estimate the current activity or predict relapse in systemic immunosuppressive drug-naïve patients with eosinophilic granulomatosis with polyangiitis?

Authors:  Juyoung Yoo; Sung Soo Ahn; Seung Min Jung; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Rheumatol Int       Date:  2019-07-13       Impact factor: 2.631

7.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

Authors:  Michael E Wechsler; Praveen Akuthota; David Jayne; Paneez Khoury; Amy Klion; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Maria C Cid; Raashid Luqmani; Judith Brown; Stephen Mallett; Richard Philipson; Steve W Yancey; Jonathan Steinfeld; Peter F Weller; Gerald J Gleich
Journal:  N Engl J Med       Date:  2017-05-18       Impact factor: 91.245

8.  Limb-Threatening Arterial Thrombosis in a Patient with Eosinophilic Granulomatosis with Polyangiitis.

Authors:  Taylor Braunberger; Jessica S Mounessa; Ryan O'Leary; Ekama Carlson; Sabrina Newman
Journal:  J Am Coll Clin Wound Spec       Date:  2017-03-27

Review 9.  Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.

Authors:  Loïc Raffray; Loïc Guillevin
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

10.  Alterations in circulating lymphoid cell populations in systemic small vessel vasculitis are non-specific manifestations of renal injury.

Authors:  B Fazekas; A Moreno-Olivera; Y Kelly; P O'Hara; S Murray; A Kennedy; N Conlon; J Scott; A M Melo; F B Hickey; D Dooley; E C O'Brien; S Moran; D G Doherty; M A Little
Journal:  Clin Exp Immunol       Date:  2017-10-20       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.